PMV has aligned with the FDA on critical aspects of the Phase 2 registrational PYNNACLE trial, with encouraging response rates observed across multiple cancer types including ovarian, breast, small-cell lung, and endometrial cancers. The company's benign safety profile enables effective combinations with other agents like Keytruda, potentially broadening treatment options.
Cyborg Score Rationale
Wall Street analysts show bullish consensus with median price target of $6.00 (328.6% upside from current $1.40 trading price), yet market cap has declined at a 42.39% compound annual rate over five years. Strong cash position of $183.3M extends runway to late 2026.
Top Insights
Recent New England Journal of Medicine publication (Feb 2026) validates rezatapopt's mechanism showing selective p53 reactivation in advanced solid tumors
Phase 2 PYNNACLE trial achieving over 90% site activation with progress toward key regulatory milestones
Cash reserves of $183.3M provide funding through late 2026, critical for reaching interim data readouts
Stock down significantly with 16.8% decline over past 12 months despite clinical progress, suggesting market skepticism on development timeline and profitability
Named Competitors
p53 Reactivation Therapies — Alternative p53 mutation targeting approaches in oncology
Recent Developments
(February 2026) New England Journal of Medicine publishes first-in-human rezatapopt data showing selective p53 reactivation in advanced solid tumors
(October 2025) PMV announces updated rezatapopt monotherapy interim data from PYNNACLE Phase 2 trial across multiple solid tumors with TP53 Y220C mutation